2,720 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Acquired by Versor Investments LP

Versor Investments LP bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,720 shares of the company's stock, valued at approximately $1,374,000.

Other hedge funds have also recently bought and sold shares of the company. Crewe Advisors LLC bought a new stake in IDEXX Laboratories in the first quarter valued at about $26,000. Ridgewood Investments LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at $27,000. Institutional & Family Asset Management LLC bought a new stake in IDEXX Laboratories in the second quarter worth $28,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after acquiring an additional 57 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC raised its position in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock valued at $34,000 after buying an additional 60 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $11.19 on Tuesday, reaching $426.11. 681,766 shares of the stock were exchanged, compared to its average volume of 500,145. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a one year low of $404.74 and a one year high of $583.39. The company's 50-day simple moving average is $471.95 and its two-hundred day simple moving average is $484.70. The firm has a market capitalization of $34.89 billion, a PE ratio of 42.17, a PEG ratio of 3.78 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same period last year, the company earned $2.53 earnings per share. IDEXX Laboratories's revenue was up 6.6% on a year-over-year basis. Analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research analyst reports. Barclays decreased their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. Piper Sandler restated a "neutral" rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research note on Thursday, October 10th. Finally, BTIG Research started coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They issued a "buy" rating and a $580.00 price objective on the stock. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.